Efficacy of recombinant human soluble thrombomodulin for childhood hemolytic uremic syndrome.

Abstract

Recombinant human soluble thrombomodulin (rhTM) is a promising therapeutic natural anticoagulant and is used clinically for the treatment of disseminated intravascular coagulation (DIC). Herein is reported the cases of two HUS children treated with rhTM. The patients were diagnosed as having typical HUS on the basis of thrombocytopenia, hemolytic anemia, acute renal failure, and the detection Escherichia coli 0157. I.v. rhTM was started as an anti-coagulant drug. At 2 days after the first treatment in both patients, fibrin/fibrinogen degradation products and d-dimer levels were significantly decreased, and there was a subsequent slight improvement in thrombocytopenia, and a decrease in serum lactate dehydrogenase level. Urinary protein excretion gradually diminished and a decrease in serum creatinine level was observed. The patients did not require dialysis therapy. The present results suggest that rhTM may be a safe and effective treatment for DIC complicated with HUS in children.

• Authors: Yukihiko Kawasaki, Kazuhide Suyama, Atsushi Ono, Tomoko Oikawa, Shinichiro Ohara, Yuichi Suzuki, Nobuko Sakai, Mitsuaki Hosoya
• Journal: Pediatrics international : official journal of the Japan Pediatric Society (Pediatr Int) Vol. 55 Issue 5 Pg. e139-42 (Oct 2013) ISSN: 1442-200X [Electronic] Australia
• PMID: 24134770 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2013 The Authors. Pediatrics International © 2013 Japan Pediatric Society.

Chemical References

• Recombinant Proteins
• THBD protein, human
• Thrombomodulin
• Creatinine

Topics

• Child, Preschool
• Creatinine (blood)
• Female
• Follow-Up Studies
• Hemolytic-Uremic Syndrome (blood, drug therapy)
• Humans
• Recombinant Proteins
• Retrospective Studies
• Thrombomodulin (therapeutic use)